American Cancer Society Revises Prostate Cancer Screening Recommendations
Just the facts

American Cancer Society Revises Prostate Cancer Screening Recommendations

Summary

The American Cancer Society now advises biennial PSA testing for average-risk men aged 50 to 69 and annual testing for Black men and those with a strong family history starting at age 45.

The American Cancer Society has issued its first update to prostate cancer screening guidelines since 2010. The new recommendations call for prostate-specific antigen (PSA) testing every two years for average-risk men aged 50 to 69, while men who are Black or have a significant family history should be screened annually beginning at age 45.

"For the first time, we are making a proactive recommendation for men to screen for prostate cancer with the prostate-specific antigen blood test," said Andrew Wolf, MD, professor emeritus of medicine at the University of Virginia School of Medicine and chair of the Society's Guideline Development Group.

Wolf added that the benefits of screening in reducing mortality and late-stage diagnoses now outweigh potential downsides. The guidelines also emphasize individualized decisions for men aged 70 to 74, recommending doctors weigh risks and benefits, and advise against routine screening for men aged 75 and older, except in select healthy individuals who discuss the issue with their physicians. Screening is not recommended for men 80 or older or for those with a life expectancy under ten years.

"PSA testing remains the cornerstone of detecting prostate cancer early, and we now have stronger evidence of its benefits," said Robert Smith, PhD, senior vice president of early cancer detection science at the Society.

The Society outlines follow-up steps for elevated PSA results, including repeat testing, confirmatory imaging or biomarker analysis, and targeted biopsy decisions. Men diagnosed with low-risk disease are advised to consider active surveillance as the initial management approach.

Wolf expressed confidence that adherence to the new guidelines will lead to a decline in prostate cancer deaths and metastatic cases in the coming years, urging men to discuss screening benefits and limitations with their health-care providers.

Keep reading — for free

Create a free account to follow the news. No card required.